-
公开(公告)号：US10072005B2
公开(公告)日：2018-09-11
申请号：US15875069
申请日：2018-01-19
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Andrew Payne , Jose Luis Castro Pineiro , Louise Michelle Birch , Afzal Khan , Alan James Braunton , James Edward Kitulagoda , Motohiro Soejima
IPC: C07D471/04 , A61K31/437 , C07D401/04
CPC classification number: C07D471/04 , C07D401/04
Abstract: 4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.
-
公开(公告)号：US08946211B2
公开(公告)日：2015-02-03
申请号：US13804691
申请日：2013-03-14
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yuichi Suzuki , Takafumi Motoki , Toshihiko Kaneko , Mamoru Takaishi , Tasuku Ishida , Yoichi Kita , Kunitoshi Takeda , Noboru Yamamoto , Afzal Khan , Paschalis Dimopoulos
IPC: C07D513/02 , A61K31/542
CPC classification number: A61K31/542 , C07D279/08 , C07D417/10 , C07D417/12 , C07D417/14 , C07D471/04 , C07D513/04
Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.
-
Patent Agency Ranking
公开(公告)号：US09926312B2
公开(公告)日：2018-03-27
申请号：US15025996
申请日：2014-09-30
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Andrew Payne , Jose Luis Castro Pineiro , Louise Michelle Birch , Afzal Khan , Alan James Braunton , James Edward Kitulagoda , Motohiro Soejima
IPC: C07D471/04 , A61K31/437 , C07D401/04
CPC classification number: C07D471/04 , C07D401/04
Abstract: 4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.
-
公开(公告)号：US20150094328A1
公开(公告)日：2015-04-02
申请号：US14501355
申请日：2014-09-30
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Andrew Payne , Jose Luis Castro Pineiro , Louise Michelle Birch , Afzal Khan , Alan James Braunton , James Edward Kitulagoda , Motohiro Soejima
IPC: C07D401/04
CPC classification number: C07D471/04 , C07D401/04
Abstract: 4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.
Abstract translation: 作为毒蕈碱乙酰胆碱受体（mAChR）M1的调节剂的4-氮杂吲哚衍生物，其可用于预防或疾病改善或对症治疗与神经系统疾病如阿尔茨海默氏型痴呆（AD）或路易体痴呆相关的认知缺陷 （DLB）和包含4-氮杂吲哚衍生物作为活性成分的药物组合物。
-
公开(公告)号：US20130203741A1
公开(公告)日：2013-08-08
申请号：US13804691
申请日：2013-03-14
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Yuichi Suzuki , Takafumi Motoki , Toshihiko Kaneko , Mamoru Takaishi , Tasuku Ishida , Yoichi Kita , Kunitoshi Takeda , Noboru Yamamoto , Afzal Khan , Paschalis Dimopoulos
IPC: A61K31/542
CPC classification number: A61K31/542 , C07D279/08 , C07D417/10 , C07D417/12 , C07D417/14 , C07D471/04 , C07D513/04
Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.
-
公开(公告)号：US20180208593A1
公开(公告)日：2018-07-26
申请号：US15875069
申请日：2018-01-19
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Andrew Payne , Jose Luis Castro Pineiro , Louise Michelle Birch , Afzal Khan , Alan James Braunton , James Edward Kitulagoda , Motohiro Soejima
IPC: C07D471/04 , C07D401/04
CPC classification number: C07D471/04 , C07D401/04
Abstract: 4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.
-
公开(公告)号：US20160244445A1
公开(公告)日：2016-08-25
申请号：US15025996
申请日：2014-09-30
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Andrew Payne , Jose Luis Castro Pineiro , Louise Michelle Birch , Afzal Khan , Alan James Braunton , James Edward Kitulagoda , Motohiro Soejima
IPC: C07D471/04
CPC classification number: C07D471/04 , C07D401/04
Abstract: 4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.
-
-
-
-
-
-
Search Results
7
records
(took 0.026 seconds)
